First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This phase I, first-in-human dose-escalation study was conducted to determine the maximum
tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs),
pharmacokinetics (PK) profile, and preliminary antitumor activity of PLB1001.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Pearl Biotechnology Limited Liability Company